Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: A multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group

导出原文传递

翻译打印收藏纠错

作者： Provencio,M. ^[1] ; CruzMora,M.A. ^[2] ; Gómez-Codina,J. ^[3] ; QueroBlanco,C. ^[4] ; Llanos,M. ^[5] ; García-Arroyo,F.R. ^[6] ; DeLaCruz,L. ^[7] ; GumáPadró,J. ^[8] ; DelgadoPérez,J.R. ^[9] ; Sánchez,A. ^[10] ; álvarezCabellos,R. ; Rueda,A.

作者单位： Hospital Universitario Pontevedra, Pontevedra, Spain ^[1] Hospital Universitario de Toledo, Toledo, Spain ^[2] Servicio de Oncología Médica, Hospital Puerta de Hierro, Madrid, Spain ^[3] Hospital Clínico de Málaga, Málaga, Spain ^[4] Hospital Costa del Sol, Marbella, Spain ^[5] Hospital Universitario Virgen Macarena, Sevilla, Spain ^[6] Hospital Universitario Virgen de las Nieves, Granade, Spain ^[7] Hospital Universitario La Fe, Valencia, Spain ^[8] Hospital Universitario de Canarias, San Cristóbal de La Laguna, Tenerife, Spain ^[9] Hospital Universitario Sant Joan de Reus, Reus, Spain ^[10]

关键词 Consolidation treatment Follicular lymphoma Yttrium-90 ibritumomab tiuxetan

发布时间 2014-04-05

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交